For instance, while the TP53 mutation, present in about 8% of adult AML cases and linked to poor outcomes, is emphasized in the European LeukemiaNet (ELN) 2022 guidelines,2 it is infrequently observed in pediatric AML. Here, TP53 is linked to acute myeloid leukemia.